30 July 2015
A new study helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body’s microbiome.img src=”http://feeds.feedburner.com/~r/sciencedaily/~4/FFKV7jFZSPI” height=”1″ width=”1″ alt=””/
http://feeds.sciencedaily.com/~r/sciencedaily/~3/FFKV7jFZSPI/150730162448.htm
